As of Oct 02
| +0.46 / +4.30%|
The 6 analysts offering 12-month price forecasts for Nektar Therapeutics have a median target of 16.00, with a high estimate of 19.00 and a low estimate of 14.00. The median estimate represents a +43.24% increase from the last price of 11.17.
The current consensus among 7 polled investment analysts is to Buy stock in Nektar Therapeutics. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.